OYLER JOHN — SEC Form 4 filings
SEC reporting owner CIK 1042047. 31 Form 4 filings on record with FilingPulse; latest filed 2026-08-12.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2024-03-14 to 2026-08-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 224 legs across 25 filings — 1,448,576 shares, $427,375,797 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 50.
- Largest priced transaction: sale of 45,044 shares @ $358.70 ($16,157,076) in BeOne Medicines Ltd., filed 2026-08-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| BeOne Medicines Ltd. (ONC) | Chief Executive Officer, Director | 31 | — | 224 legs · 1,448,576 sh · $427,375,797 | 50 |
Form 4 filings — OYLER JOHN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-12 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 67 @ $350 · Sale (S): 2,813 @ $351.80 · Sale (S): 3,673 @ $353.32 · Sale (S): 6,717 @ $354.78 · Sale (S): 3,476 @ $355.66 · Sale (S): 12,418 @ $356.62 · +18 more | EDGAR |
| 2026-07-22 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 5,146 @ $310.08 · Sale (S): 6,273 @ $310.75 · Sale (S): 2,907 @ $311.80 · Option exercise (M): 33,990 @ $119.96 · Sale (S): 15,499 @ $312.29 · Sale (S): 14,326 @ $312.96 · +10 more | EDGAR |
| 2026-07-17 | 4 | BeOne Medicines Ltd. (ONC) | Option exercise (M): 35,605 @ $100.04 · Option exercise (M): 76,677 @ $169.58 · Option exercise (M): 4,275 @ $160.40 · Sale (S): 6,067 @ $310.02 · Sale (S): 41,336 @ $310.92 · Sale (S): 12,857 @ $311.71 · +21 more | EDGAR |
| 2026-07-17 | 4 | BeOne Medicines Ltd. (ONC) | Option exercise (M): 64,628 @ $119.96 · Sale (S): 1,440 @ $305.20 · Sale (S): 597 @ $306.96 · Sale (S): 680 @ $309.05 · Sale (S): 4,833 @ $310.37 · Sale (S): 5,543 @ $311.42 · +5 more | EDGAR |
| 2026-07-14 | 4 | BeOne Medicines Ltd. (ONC) | Option exercise (M): 11,698 @ $36.90 · Sale (S): 1,493 @ $296.07 · Sale (S): 1,314 @ $297.23 · Sale (S): 3,074 @ $298.35 · Sale (S): 5,143 @ $298.94 · Sale (S): 370 @ $300.12 · +13 more | EDGAR |
| 2026-07-14 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 4,139 @ $303.07 · Sale (S): 8,122 @ $303.93 · Option exercise (M): 97,282 @ $36.90 · Option exercise (M): 36,318 @ $100.04 · Sale (S): 39,090 @ $305.02 · Sale (S): 45,895 @ $306.21 · +4 more | EDGAR |
| 2026-06-25 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 1,800 @ $273.30 · Sale (S): 1,290 @ $274.12 · Sale (S): 320 @ $275.10 | EDGAR |
| 2026-06-18 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 1,650 @ $264.87 · Sale (S): 1,710 @ $265.99 · Sale (S): 333 @ $266.69 | EDGAR |
| 2026-06-15 | 4 | BeOne Medicines Ltd. (ONC) | Grant/award (A): 177,931 @ $0 · Sale (S): 741 @ $256.23 · Sale (S): 859 @ $257.59 · Sale (S): 200 @ $258.28 · Sale (S): 149 @ $258.81 · Grant/award (A): 344,669 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 3,820 @ $270.38 · Sale (S): 1,120 @ $271.14 | EDGAR |
| 2026-03-10 | 4 | BeOne Medicines Ltd. (ONC) | Grant/award (A): 326,976 @ $0 · Grant/award (A): 117,936 @ $0 | EDGAR |
| 2025-12-17 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 1,791 @ $301.58 · Sale (S): 6,389 @ $302.29 · Sale (S): 1,896 @ $303.60 · Sale (S): 5,829 @ $304.37 · Sale (S): 3,940 @ $305.55 · Sale (S): 4,949 @ $306.39 · +18 more | EDGAR |
| 2025-11-13 | 4 | BeOne Medicines Ltd. (ONC) | Gift (G): 151,320 @ $0 · Gift (G): 858,533 @ $0 | EDGAR |
| 2025-09-18 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 4,066 @ $324.12 · Sale (S): 6,883 @ $325.06 · Sale (S): 12,446 @ $326.14 · Sale (S): 4,008 @ $326.90 · Sale (S): 400 @ $327.78 | EDGAR |
| 2025-07-11 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 6,703 @ $252.23 · Sale (S): 9,292 @ $253.18 · Sale (S): 10,254 @ $254.10 · Sale (S): 1,553 @ $254.83 | EDGAR |
| 2025-06-25 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 3,074 @ $261.57 · Sale (S): 100 @ $262.90 | EDGAR |
| 2025-06-18 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 3,680 @ $266.05 · Sale (S): 1,460 @ $256.49 | EDGAR |
| 2025-06-12 | 4 | BeOne Medicines Ltd. (ONC) | Grant/award (A): 185,055 @ $0 · Grant/award (A): 348,374 (derivative) @ $0 | EDGAR |
| 2025-06-10 | 4 | BeOne Medicines Ltd. (ONC) | Sale (S): 1,400 @ $250.84 · Sale (S): 1,400 @ $251.88 · Sale (S): 1,000 @ $253.49 · Sale (S): 927 @ $254.97 · Sale (S): 400 @ $255.74 | EDGAR |
| 2025-05-13 | 4 | BeiGene, Ltd. (BGNE) | Option exercise (M): 4,055,415 @ $0.50 · Tax withholding (F): 1,990,603 @ $17.85 · Option exercise (M): 4,055,415 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | BeiGene, Ltd. (BGNE) | Option exercise (M): 497,822 @ $0.50 · Option exercise (M): 41,210 @ $6.50 · Sale (S): 1,900 @ $238.74 · Sale (S): 6,800 @ $239.59 · Sale (S): 2,200 @ $240.70 · Sale (S): 7,069 @ $241.92 · +6 more | EDGAR |
| 2025-03-07 | 4 | BeiGene, Ltd. (BGNE) | Grant/award (A): 201,084 @ $0 · Option exercise (M): 486,161 @ $0.50 · Option exercise (M): 40,109 @ $6.50 · Sale (S): 3,500 @ $256.91 · Sale (S): 13,598 @ $257.92 · Sale (S): 8,200 @ $258.91 · +6 more | EDGAR |
| 2025-03-07 | 4 | BeiGene, Ltd. (BGNE) | Option exercise (M): 708,747 @ $0.50 · Option exercise (M): 58,590 @ $6.50 · Sale (S): 1,400 @ $246.03 · Sale (S): 2,100 @ $246.09 · Sale (S): 1,190 @ $246.69 · Sale (S): 13,918 @ $246.91 · +10 more | EDGAR |
| 2025-03-05 | 4 | BeiGene, Ltd. (BGNE) | Option exercise (M): 1,220,531 @ $0.50 · Option exercise (M): 101,000 @ $6.50 · Sale (S): 5,956 @ $240.53 · Sale (S): 13,816 @ $241.38 · Sale (S): 8,192 @ $242.46 · Sale (S): 11,195 @ $243.44 · +9 more | EDGAR |
| 2024-12-17 | 4 | BeiGene, Ltd. (BGNE) | Option exercise (M): 1,300,000 @ $0.50 · Option exercise (M): 1,300,000 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | BeiGene, Ltd. (BGNE) | Sale (S): 1,565 @ $229.25 · Sale (S): 1,747 @ $230.05 · Sale (S): 229 @ $231.05 · Sale (S): 38 @ $233 · Sale (S): 428 @ $234.27 · Sale (S): 1,272 @ $235.41 · +8 more | EDGAR |
| 2024-06-26 | 4 | BeiGene, Ltd. (BGNE) | Sale (S): 2,389 @ $159.49 · Sale (S): 400 @ $160.12 | EDGAR |
| 2024-06-20 | 4 | BeiGene, Ltd. (BGNE) | Sale (S): 297 @ $158.53 · Sale (S): 608 @ $159.40 · Sale (S): 376 @ $159.91 | EDGAR |
| 2024-06-07 | 4 | BeiGene, Ltd. (BGNE) | Grant/award (A): 490,464 @ $0 · Grant/award (A): 923,975 (derivative) @ $0 | EDGAR |
| 2024-04-11 | 4 | BeiGene, Ltd. (BGNE) | Sale (S): 542 @ $152.28 · Sale (S): 2,734 @ $153.47 · Sale (S): 7,924 @ $154.21 · Sale (S): 11,514 @ $148.40 · Sale (S): 12,501 @ $149.15 · Sale (S): 2,641 @ $149.79 · +4 more | EDGAR |
| 2024-03-14 | 4 | BeiGene, Ltd. (BGNE) | Sale (S): 6,598 @ $162.74 · Sale (S): 15,466 @ $163.78 · Sale (S): 12,069 @ $164.49 · Sale (S): 2,602 @ $165.49 · Sale (S): 733 @ $166.44 · Sale (S): 200 @ $169.05 · +8 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1042047 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →